Maze officer plans sale of 10,685 shares

Maze Therapeutics, Inc. (MAZE) has a notice of proposed sale of common stock under Rule 144 filed for officer Harold Bernstein.

Rhea-AI Filing Summary

Maze Therapeutics, Inc. (MAZE) has a notice of proposed sale of common stock under Rule 144 filed for officer Harold Bernstein. Bernstein plans to sell 10,685 shares of common stock through Morgan Stanley Smith Barney LLC, with the shares arising from restricted stock units that vested on September 1, 2026.

The shares relate to an equity incentive award, and the company states the reported sale was mandated by the issuer and includes an amount necessary to satisfy tax withholding obligations from the vesting and settlement of those restricted stock units. The notice also lists several prior sales of Maze Therapeutics common stock by Bernstein over the past three months.

Key Figures

Shares to be sold under Rule 144: 10,685 shares of common stock Shares sold on July 1, 2026: 14,609 shares for $436,864.07 Shares sold on August 13, 2026: 16,142 shares for $445,620.89 +2 more

5 metrics

Shares to be sold under Rule 144 10,685 shares of common stock Proposed sale by Harold Bernstein disclosed in the notice

Shares sold on July 1, 2026 14,609 shares for $436,864.07 Maze Therapeutics common stock sold by Harold Bernstein in past three months

Shares sold on August 13, 2026 16,142 shares for $445,620.89 Maze Therapeutics common stock sold by Harold Bernstein in past three months

Shares sold on September 1, 2026 16,141 shares for $425,512.27 Maze Therapeutics common stock sold by Harold Bernstein in past three months

Date of Notice September 2, 2026 Date Harold Bernstein signed the Rule 144 notice

Key Terms

Rule 144, Restricted Stock Unit Vesting, equity incentive award, tax withholding obligations

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Unit Vesting financial

"Common Stock | 09/01/2026 | Restricted Stock Unit Vesting | Issuer"

equity incentive award financial

"restricted stock units granted pursuant to an equity incentive award."

Equity incentive award is a grant of company ownership or the right to buy ownership—such as stock, restricted shares, or options—given to employees, executives, or directors as part of their pay. Investors care because these awards align workers’ interests with shareholders (like giving someone slices of a pie so they try to make the pie bigger), but they also dilute existing ownership and increase reported compensation costs, which can affect share value and earnings per share.

tax withholding obligations financial

"includes an amount necessary to satisfy tax withholding obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for MAZE?

It discloses that officer Harold Bernstein plans to sell 10,685 shares of Maze Therapeutics common stock under Rule 144, with the shares coming from vested restricted stock units granted under an equity incentive award.

How many MAZE shares is Harold Bernstein proposing to sell now?

The notice states that Harold Bernstein proposes to sell 10,685 shares of common stock of Maze Therapeutics through Morgan Stanley Smith Barney LLC, with the transaction tied to restricted stock units that vested on September 1, 2026.

What is the source of the MAZE shares being sold by Harold Bernstein?

The filing states the sale relates to restricted stock units vesting on September 1, 2026, granted under an equity incentive award, and includes shares necessary to satisfy tax withholding obligations from that vesting and settlement.

What MAZE stock sales has Harold Bernstein made in the past three months?

The notice lists Maze Therapeutics common stock sales of 14,609 shares for $436,864.07 on July 1, 2026, 16,142 shares for $445,620.89 on August 13, 2026, and 16,141 shares for $425,512.27 on September 1, 2026.

Which broker is handling the proposed MAZE share sale?

The proposed sale of 10,685 Maze Therapeutics common shares for Harold Bernstein is listed as being through Morgan Stanley Smith Barney LLC Executive Financial Services at 1 New York Plaza in New York.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 07:00 PM EDT Accepted by SEC EDGAR 09/02/2026 - 07:00 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002050172
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MAZE THERAPEUTICS, INC.
SEC File Number	001-42490
Address of Issuer	171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	650-850-5070
Name of Person for Whose Account the Securities are To Be Sold	Harold Bernstein
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza, 8th Floor New York NY 10004	10685	283500	55549168	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/01/2026	Restricted Stock Unit Vesting	Issuer			10685	09/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Harold Bernstein c/o Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080	Common Stock	07/01/2026	14609	436864.07
Harold Bernstein c/o Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080	Common Stock	08/13/2026	16142	445620.89
Harold Bernstein c/o Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080	Common Stock	09/01/2026	16141	425512.27

144: Remarks and Signature

Remarks	The reported sale was mandated by the Issuer and includes an amount necessary to satisfy tax withholding obligations resulting from the vesting and settlement of restricted stock units granted pursuant to an equity incentive award.
Date of Notice	09/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Harold Bernstein
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)